Clinical trials: Anticoagulant Drugs
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03578146
- Testing
- PRT064445/Rivaroxaban
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Atrial Fibrillation
The Effect Of Face-To-Face and Online-Education Provided To İndividuals With Atrial Fibrillation On Medication Adherence and Satisfaction
This randomized controlled study was conducted to investigate the effects of face-to-face Education and tele-education given to individuals with atrial fibrillation taking oral Anticoagulants on their medication compliance and…
- Trial name
- NCT06233721
- Testing
- Online education, Face-to-face education
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Cumhuriyet University
Coronary Artery Disease
Anticoagulant Treatments and Percutaneous Coronary Angioplasty
The purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous…
- Trial name
- TACA (NCT00669149)
- Testing
- clopidogrel + aspirin, heparin + clopidogrel + aspirin, enoxaparin + clopidogrel + aspirin
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier de PAU
Venous Thromboembolism
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors.
- Trial name
- REVNEWANTICO (NCT01210755)
- Testing
- Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Severe Preeclampsia, Antiphospholipid Syndrome
Antiphospholipid Antibodies and Early Severe Preeclampsia.
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and…
- Trial name
- NCT01538121
- Where
- Panama
- Volunteers
- 310 people
- Sponsor
- Saint Thomas Hospital, Panama
Significant Bleeding Risk
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex®…
- Trial name
- NCT02740335
- Testing
- Octaplex, Beriplex P/N (Kcentra)
- Where
- 86 sites in United States, Belarus and 9 more
- Volunteers
- 208 people
- Sponsor
- Octapharma
Radiation Cystitis, Non-valvular Atrial Fibrillation
Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding
The etiology of the radiation cystitis is a pelvic irradiation generally performed as part of the treatment of prostate cancer. The incidence is 50,000 new cases per year.
- Trial name
- HEMOCC (NCT04701749)
- Testing
- Percutaneous left atrial closure, No Percutaneous left atrial closure
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
Venous Thromboembolism
Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant
The objectives of this registry are to measure the outcomes, cost, adherence pattern and experience of patients treated as outpatients with rivaroxaban after being diagnosed with blood clots in the emergency department.
- Trial name
- NCT02079584
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Indiana University
Anticoagulants and Bleeding Disorders
Evaluating LumiraDx INR Test Accuracy in Patients Taking Phenprocoumon Anticoagulant.
This study is to evaluate the INR levels in patients taking phenprocoumon using the LumiraDx Point of Care INR test and comparing the results to the laboratory reference method , the ACL Elite Pro.
- Trial name
- VKA_GERMANY (NCT04074980)
- Testing
- Venous and Fingerstick blood draws, Venous blood draw
- Where
- Germany
- Volunteers
- 102 people
- Sponsor
- LumiraDx UK Limited
Atrial Fibrillation
Global Anticoagulant Registry in the Field
The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients.
- Trial name
- GARFIELD-AF (NCT01090362)
- Where
- 35 sites in United States, Argentina and 33 more
- Volunteers
- 57,250 people
- Sponsor
- Thrombosis Research Institute
Atrial Fibrillation, Frailty
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with…
- Conditions
- Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding, Stroke
- Trial name
- NCT04878497
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation New Onset
CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection
This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.
- Trial name
- NCT05127460
- Testing
- AI-enabled ECG-based Screening Tool
- Where
- Taiwan
- Volunteers
- 25,732 people
- Sponsor
- National Defense Medical Center, Taiwan
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Deep Vein Thrombosis, Iliac Vein Thrombosis
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who…
- Conditions
- Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction, Iliac Vein Stenosis
- Trial name
- NCT04694248
- Testing
- Rivaroxaban, Aspirin
- Where
- China
- Volunteers
- 172 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Lower Extremity Injuries, Venous Thromboembolism (VTE)
TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring Immobilization
This is a prospective, multicenter, observational cohort study designed to externally validate the Trauma-Related Immobilization-related Prophylaxis (TRiP(cast)) score in Tunisian adults with acute lower-limb trauma requiring…
- Conditions
- Lower Extremity Injuries, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- TRiP-VALID (NCT07863115)
- Testing
- Low-Molecular-Weight Heparin (LMWH), Direct Oral Anticoagulants (DOACs), No Thromboprophylaxis Cohort
- Where
- Tunisia
- Volunteers
- 1,500 people
- Sponsor
- University of Monastir
Lymphoma, Multiple Myeloma
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
In cancer, the incidence of venous thromboembolism (VTE) is particularly high in patients with myeloma, especially when it is de novo and treated with thalidomide, lenalidomide or erythropoietin.
- Trial name
- METRO B (NCT02260414)
- Testing
- Tinzaparin, Blood sample
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Anticoagulant-induced Bleeding, Intracranial Hemorrhages
Anticoagulant-associated Intracranial Hemorrhage
Oral anticoagulant therapy, including factors Xa and 2a inhibitors has become more popular in recent years due to its efficacy and convenience in preventing thrombotic events and reducing the risk for stroke in patients with rosk…
- Trial name
- AAIHINNN (NCT06168838)
- Testing
- Anticoagulant
- Where
- Mexico
- Volunteers
- 1,200 people
- Sponsor
- El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Atrial Fibrillation, Deep Vein Thrombosis
Pharmacogenetics of Warfarin in Puerto Ricans.
Warfarin (Coumadin) is a prescribed "blood thinner" medication used to make the blood less thick in people with high risk of forming blood clots.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Antiphospholipid Syndrome
- Trial name
- NCT01318057
- Where
- Puerto Rico
- Volunteers
- 350 people
- Sponsor
- University of Puerto Rico
Coronary Artery Disease, Percutaneous Coronary Intervention
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- NCT05638867
- Testing
- Aspirin + Clopidogrel + Rivaroxaban, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 3,944 people
- Sponsor
- China National Center for Cardiovascular Diseases